Investigational drug · Phase 3
Tacabrutideg
Also called: BGB-16673
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Lymphocytic Leukemia, B-cell Malignancy, Small Lymphocytic Lymphoma.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
11
Any phase or sponsor naming "Tacabrutideg"
First trial start
2021
Sep 13, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tacabrutideg", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Lymphocytic Leukemia
- B-cell Malignancy
- Small Lymphocytic Lymphoma
- Non-Hodgkin Lymphoma
- Mantle Cell Lymphoma
- Waldenström Macroglobulinemia
- Marginal Zone Lymphoma
- Follicular Lymphoma
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- DLBCL Unclassifiable
Approved drugs for the same conditions: Chronic lymphocytic leukemia · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Tacabrutideg" as an intervention, largest first.
- A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell MalignanciesPivotal-lookingRecruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT05006716 · 689 participants (planned) · Start Sep 13, 2021 · Primary completion Mar 2027
Drug: Tacabrutideg · For: B-cell Malignancy; Marginal Zone Lymphoma; Follicular Lymphoma and 7 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 114 sites in all
- A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaPivotal-lookingRecruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT06973187 · 500 participants (planned) · Start Sep 4, 2025 · Primary completion Apr 17, 2028
Drug: Tacabrutideg; Pirtobrutinib · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Birmingham, Alabama; Phoenix, Arizona; Irvine, California · 217 sites in all
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT06846671 · 250 participants (planned) · Start Apr 10, 2025 · Primary completion May 15, 2028
Drug: Tacabrutideg; Bendamustine and 3 more · For: CLL; Chronic Lymphocytic Leukemia; SLL
Sites: Jonesboro, Arkansas; Los Angeles, California; San Diego, California · 134 sites in all
- A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) InhibitorsPivotal-lookingActive, not recruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT06970743 · 153 participants · Start May 29, 2025 · Primary completion Nov 30, 2029
Drug: BGB-16673; Bendamustine and 4 more · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Hefei, China; Beijing, China; Chongqing, China · 56 sites in all
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT05294731 · 146 participants (planned) · Start May 6, 2022 · Primary completion Jun 30, 2027
Drug: Tacabrutideg · For: B-cell Malignancy; Non-Hodgkin Lymphoma; Mantle Cell Lymphoma and 6 more
Sites: Bengbu, China; Hefei, China; Beijing, China · 29 sites in all
Massachusetts General HospitalAcademic, hospital or other
NCT06849713 · 80 participants (planned) · Start May 16, 2025 · Primary completion Mar 1, 2028
Drug: Zanubrutinib; Sonrotoclax and 2 more · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma (SLL)
Sites: Boston, Massachusetts; New York, New York
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT06634589 · 80 participants (planned) · Start Nov 27, 2024 · Primary completion Dec 2, 2028
Drug: Tacabrutideg; Sonrotoclax and 4 more · For: B-cell Malignancy; Relapsed Cancer; Refractory Cancer and 1 more
Sites: Phoenix, Arizona; Los Angeles, California; Jacksonville, Florida · 49 sites in all
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT07005713 · 58 participants (planned) · Start Jul 19, 2025 · Primary completion Nov 30, 2026
Drug: Tacabrutideg; Placebo · For: Chronic Spontaneous Urticaria
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 9 sites in all
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT06906809 · 37 participants · Start Apr 3, 2025 · Primary completion Oct 13, 2025
Drug: BGB-16673; Itraconazole and 1 more · For: Healthy Volunteers
Sites: Madison, Wisconsin
- Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Not yet recruiting
Fred Hutchinson Cancer CenterAcademic, hospital or other
NCT07887061 · 30 participants (planned) · Start Jan 1, 2027 · Primary completion Jul 1, 2031
Drug: Tacabrutideg; Sonrotoclax and 1 more · For: Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Small Lymphocytic Lymphoma
Sites: Seattle, Washington
Newest research
PubMed records naming it or its code names, newest first.
- PROTAC degraders for lymphoid malignancies - current status and future directions.
Wolska-Washer A, Robak T · Expert Opin Emerg Drugs 2026
- BTK/BCL2 dual targeting enhances apoptosis in marginal zone lymphoma: preclinical activity of tacabrutideg (BGB-16673) and sonrotoclax.
Arribas AJ, Zadro A, Civanelli E, et al. · Haematologica 2026
- Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting.
Sharma P, Jiang H, Liu D · J Hematol Oncol 2026
- Invasive Cutaneous Mucormycosis in a Patient With Chronic Lymphocytic Leukemia on Obinutuzumab, Idelalisib, and Bruton Tyrosine Kinase Degrader: A Case Report.
Morinishi CD, Brown CE, Younes R · Cureus 2025
- Resistance Mutations in CLL: Genetic Mechanisms Shaping the Future of Targeted Therapy.
Sekeres S, Lamkin EN, Bravo E, et al. · Genes (Basel) 2025
- Diagnosis and Management of Waldenstrom's Macroglobulinemia.
Treon SP, Sarosiek S, Castillo JJ · Hematol Oncol 2025
Also in development for Chronic Lymphocytic Leukemia
- APG-2575lisaftoclaxPhase 310 trials
Ascentage Pharma Group Inc. · CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials
Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia
- NemtabrutinibMK-1026, ARQ 531Phase 36 trials
Merck & Co. · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
- KRT-232NavtemadlinPhase 34 trials
Kartos Therapeutics, Inc. · Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- NX-5948bexobrutidegPhase 33 trials
Nurix Therapeutics, Inc. · B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- CLR 131I-131-CLR1404, Iopofosine I 131 single dosePhase 32 trials
Cellectar Biosciences, Inc. · Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia
- EmavusertibCA-4948Phase 22 trials
Curis, Inc. · Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from BeOne Medicines (BeiGene).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.